You can access any of the podium or poster presentations’ abstracts by searching for it below. For the 2026 FIP world congress in Montreal, presentations and summaries from invited speakers are available below, while abstracts are published in the Pharmacy Education Journal (PEJ) here.
Export this Abstract | Print this Abstract |
Add to my preferred Abstracts list |
My preferred Abstracts list (0) |
Back to Search
Comparison of efficacy and safety between generic and brand formulations of ceftriaxone
- In: Hospital Pharmacy - Posters
- At: Basel (Switzerland) (2008)
- Type: Poster
- Poster code: HPS-P-048
- By: CHEN, Yi-Hsiu (Tzu Chi General Hospital Taipei Branch, Taipei, China Taiwan)
- Co-author(s): Wu, Ta-Wei (Tzu Chi General Hospital Taipei Branch, TAIPEI, China Taiwan)
- Abstract:
After altering the manufacturer of ceftriaxone on Aug 6 2007, physicians responded that the clinical outcomes of brand formulations (denoted Ceftriaxone-B) were more superior than generic formulations (denoted Ceftriaone-G ). In our pilot study, fever reduction attained in 10/34 (29.4%) patients after using Ceftriaxone-B and in 6/36 (16.7%)..
The access to the whole abstract and if available the presentation file is available to FIP members and to congress participants of that specific congress.
Please login
Last update 23 September 2026